Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke (IRIS) Trial
Explore this paper's citation graph
Summary
The IRIS Trial will determine whether treatment with pioglitazone improves cardiovascular outcomes of non-diabetic, insulin-resistant patients with stroke or TIA, and results are expected in early 2016.
- Type
- book
- Published
- 2014-07-28
- Cited by
- 50
- References
- 49
- Access
- Open access
- OpenAlex
- https://openalex.org/W25458644
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:20483066
Keywords
Security management, Business, Computer security, Computer science
References
- NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.
- Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
- A population based study
- Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
- Mild Dementia or Cognitive Impairment: The Modified Mini-Mental State Examination (3MS) as a Screen for Dementia
- Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.
- Comment on the provisional report from the WHO consultation
- Insulin resistance in noninsulin-dependent diabetes mellitus. Does it exist and can it be measured?
- Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study.
- Insulin resistance in the vasculature.
- An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
- Discrete sequential boundaries for clinical trials
- Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.
- Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
- A Prospective Analysis of the HOMA Model: The Mexico City Diabetes Study
- Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
- Analysis of longitudinal data
- Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke
- Long-Term Outcome after Ischaemic Stroke/Transient Ischaemic Attack
- Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis
Cited by
- Nontraditional Risk Factors for Ischemic Stroke: An Update
- Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
- Arterial age as a substitute for chronological age in the AGLA risk function could improve coronary risk prediction.
- PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- Pioglitazone use and risk of bladder cancer: population based cohort study
- Higher Insulin Resistance Level is Associated with Worse Clinical Response in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis
- Glucose-lowering therapy in type 2 diabetes
- Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning?
- The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
- Composite Scores and Other Outcome Measures in Stroke Trials.
- Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
- Taking care of volunteers in a stroke trial: a new assisted-management strategy
- Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
- Pioglitazone and cardiovascular risk reduction: time for a second look?
- Reducing sedentary time and fat mass may improve glucose tolerance and insulin sensitivity in adults surviving 6 months after stroke: A phase I pilot study
- Insulin resistance in ischemic stroke
- Hyperglycaemia in acute intracerebral haemorrhage
- Smoking cessation and outcome after ischemic stroke or TIA
- Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction